A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti–interferon-alfa monoclonal antibody, in subjects with chronic psoriasis

2010 ◽  
Vol 62 (3) ◽  
pp. 427-436 ◽  
Author(s):  
Robert Bissonnette ◽  
Kim Papp ◽  
Catherine Maari ◽  
Yihong Yao ◽  
Gabriel Robbie ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Phase I Study ◽  
Interferon Alfa ◽  
Double Blind ◽  
Double Blind Placebo

Randomised, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I Study of QGC001, a Centrally Acting Aminopeptidase A Inhibitor Prodrug

2013 ◽  
Vol 53 (4) ◽  
pp. 385-395 ◽  
Author(s):  
Fabrice Balavoine ◽  
Michel Azizi ◽  
Damien Bergerot ◽  
Nadia De Mota ◽  
Rémi Patouret ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Study ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Aminopeptidase A ◽  
Aminopeptidase A Inhibitor ◽  
Dose Escalating

NXY-059 Does Not Affect Bleeding Time in Healthy Volunteers: A Randomized, Double-Blind, Placebo-Controlled, 3-Period Crossover Phase I Study

2007 ◽  
Vol 47 (2) ◽  
pp. 264-272 ◽  
Author(s):  
Dag Nilsson ◽  
Johan Wemer ◽  
Yi-Fang Cheng ◽  
Ingalill Reinholdsson ◽  
Gunnar Englund ◽  
...  
Keyword(s):  
Phase I ◽  
Healthy Volunteers ◽  
Phase I Study ◽  
Bleeding Time ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Crossover Phase
Sign in / Sign up

Export Citation Format

Share Document